Search Results - "P. Bruggmann"

Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers by Bruggmann, P.

“…Summary With the arrival of simple, efficient and safe interferon‐free treatment regimens, hepatitis C virus (HCV) therapy will have the potential to be…”
Get full text

Direct-acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data by Scherz, N, Brunner, N, Bruggmann, P

Get full text

Trends in hepatitis C‐related mortality in Switzerland by Keiser, O., Giudici, F., Müllhaupt, B., Junker, C., Dufour, J. ‐F., Moradpour, D., Bruggmann, P., Terziroli, B., Semela, D., Brezzi, M., Bertisch, B., Estill, J., Negro, F., Spoerri, A.

“…Summary In order to accurately assess the burden of hepatitis C (HCV) and develop effective interventions, we must understand the magnitude and trends of…”
Get full text

Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study by Bruggmann, P, Dampz, M, Gerlach, T, Kravecz, L, Falcato, L

“…Abstract Background Adherence to hepatitis C treatment is influenced by alcohol as is the action of interferon; yet the clinical significance of the latter…”
Get full text

Participation, retention and uptake in a multicentre pre‐exposure prophylaxis cohort using online, smartphone‐compatible data collection by Hovaguimian, F, Martin, E, Reinacher, M, Rasi, M, Schmidt, AJ, Bernasconi, E, Boffi El Amari, E, Braun, DL, Calmy, A, Darling, K, Christinet, V, Depmeier, C, Hauser, C, Läuchli, S, Notter, J, Stoeckle, M, Surial, B, Vernazza, P, Bruggmann, P, Tarr, P, Haerry, D, Bize, R, Low, N, Lehner, A, Böni, J, Kouyos, RD, Fehr, JS, Hampel, B

“…Objectives The aim of the study was to assess the feasibility of a national pre‐exposure prophylaxis (PrEP) programme using smartphone‐compatible data…”
Get full text

Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue by Razavi, H., Bruggmann, P., Wedemeyer, H., Dore, G.

Get full text

Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients by Bruggmann, P., Falcato, L., Dober, S., Helbling, B., Keiser, O., Negro, F., Meili, D.

“…Reluctance has been expressed about treating chronic hepatitis C in active intravenous (IV) drug users (IDUs), and this is found in both international…”
Get full text

Trends in Hepatitis C-related mortality in Switzerland by Keiser, O, Giudici, F, Bruggmann, P, Dufour, J.-F, Moradpour, D, Semela, D, Heim, M, Müllhaupt, B, Beretta-Piccoli, B.T, Malinverni, R, Negro, F, Spörri, A

Get full text

Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse by Lamoury, F, Soker, A, Martinez, D, Hajarizadeh, B, Cunningham, E, Bruggmann, P, Foster, G, Dalgard, O, Conway, B, Robaeys, G, Swan, T, Backmund, M, Marks, P, Grebely, J, Dore, G.J, Applegate, T.L

Get full text

P1285 THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN SWITZERLAND by Bruggmann, P, Negro, F, Bihl, F, Hindman, S, Lavanchy, D, Müllhaupt, B, Razavi, H, Semela, D

Get full text

Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study by Grebely, J, Dalgard, O, Conway, B, Cunningham, E, Bruggmann, P, Hajarizadeh, B, Amin, J, Marks, P, Quiene, S, Applegate, T.L, Swan, T, Byrne, J, Lacalamita, M, Dunlop, A.J, Bruneau, J, Hellard, M.E, Matthews, G.V, Powis, J, Shaw, D, Thurnheer, C.M, Weltman, M, Kronborg, I, Cooper, C, Feld, J.J, Fraser, C, Litwin, A, Dillon, J, Read, P, Gane, E, Dore, G.J

Get full text

Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe by Marshall, A.D, Nielsen, S, Cunningham, E.B, Aghemo, A, Alho, H, Backmund, M, Bruggmann, P, Dalgard, O, Flisiak, R, Foster, G, Gheorghe, L, Goldberg, D, Goulis, I, Hickman, M, Hoffmann, P, Jancorienė, L, Jarčuška, P, Kåberg, M, Makara, M, Maimets, M, Marinho, R, Matičič, M, Norris, S, Olafsson, S, Øvrehus, A, Pawlotsky, J.-M, Pocock, J, Robaeys, G, Roncero, C, Simonova, M, Sperl, J, Tait, M, Tolmane, I, Tomaselli, S, van der Valk, M, Vince, A, Dore, G.J, Lazarus, J.V, Grebely, J

Get full text

P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study by Grebely, J, Dalgard, O, Conway, B, Foster, G, Bruggmann, P, Backmund, M, Robaeys, G, Swan, T, Hajarizadeh, B, Amin, J, Marks, P, Quiene, S, Weltman, M, Shaw, D, Dunlop, A, Hellard, M, Bruneau, J, Bourgeois, S, Thurnheer, C, Dore, G.J

Get full text

771 ALCOHOL CONSUMPTION DURING HEPATITIS C THERAPY IN PATIENTS OF THE SWISS HEPATITIS C COHORT STUDY by Bruggmann, P, Dampz, M, Falcato, L.M

Get full text

[577] SUCCESSFUL TREATMENT OF HEPATITIS C RESULTING FROM INJECTING DRUG USE: RESULTS OF THE SWISS HEPATITIS C COHORT STUDY by Bruggmann, P, Dober, S, Isler, M, Meili, D

Get full text

O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study by J. Grebely, O. Dalgard, B. Conway, E. Cunningham, P. Bruggmann, B. Hajarizadeh, J. Amin, P. Marks, S. Quiene, T.L. Applegate, T. Swan, J. Byrne, M. Lacalamita, A. Dunlop, J. Bruneau, M.E. Hellard, G.V. Matthews, J. Powis, D. Shaw, M.C. Thurnheer, M. Weltman, I. Kronborg, C. Cooper, J.J. Feld, C. Fraser, A. Litwin, J. Dillon, P. Read, E. Gane, G.J. Dore

Get full text

772 ACTIVE INTRAVENOUS DRUG USE DURING CHRONIC HEPATITIS C THERAPY DOES NOT REDUCE SUSTAINED VIROLOGIC RESPONSE RATES IN ADHERENT PATIENTS by Bruggmann, P, Falcato, L.M, Helbling, B, Keiser, O, Dober, S, Negro, F, Meili, D

Get full text

Management of hepatitis C virus (HCV) infection in drug substitution programs by Witteck, Andrea, Schmid, Patrick, Hensel-Koch, Katharina, Thurnheer, Maria C, Bruggmann, Philip, Vernazza, Pietro

“…In Switzerland, intravenous drug use (IDU) accounts for 80% of newly acquired hepatitis C virus (HCV) infections. Early HCV treatment has the potential to…”
Get full text

Adherence to the Swiss guidelines for management of COPD: experience of a Swiss teaching hospital by Fritsch, K, Jacot, M-L, Klarer, A, Wick, F, Bruggmann, P, Krause, M, Thurnheer, R

“…Swiss guidelines for the management of chronic obstructive pulmonary disease (COPD) were published in 2002. We aimed at assessing adherence to the proposed…”
Get full text

SAT-245 - Direct-acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data by Scherz, N., Brunner, N., Bruggmann, P.

Get full text